Prefrontal cortex and executive function impairments in primary breast cancer

Archives of Neurology

Volumn 68, Issue 11, 2011, Pages 1447-1453

  Kesler, Shelli R ^a,b   Kent, Jamie S ^b   O'Hara, Ruth ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADULT; AGING; ARTICLE; BRAIN FUNCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; OBSERVATIONAL STUDY; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PREFRONTAL CORTEX; PSYCHOMOTOR PERFORMANCE;

EID: 81355154161     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.245     Document Type: Article

References (37)

1. International Agency for Research on Cancer. Breast cancer incidence and mortality worldwide in 2008: summary. GLOBOCAN/International Agency for Research on Cancer Web site. http://globocan.iarc.fr/factsheets/cancers/breast.asp. Accessed July 9, 2011.
2. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123(3):819-828.
3. de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206-1219.
4. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103(3):303-311. (Pubitemid 46944511)
5. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109(1):146-156. (Pubitemid 46120202)
6. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8(1):88-91. (Pubitemid 351346234)
7. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866-3870. (Pubitemid 47477262)
8. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D. Regional brain activation during verbal declarative memory inmetastatic breast cancer. Clin Cancer Res. 2009;15(21):6665-6673.
9. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434-4440.
10. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223-232.
11. Cimprich B, Reuter-Lorenz P, Nelson J, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32(3):324-331.
12. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. "Chemobrain"in breast carcinoma? a prologue. Cancer. 2004;101(3):466-475.
13. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143-152. (Pubitemid 351793851)
14. Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J. 2008;14(6):396-400.
15. Glover GH, Lai S. Self-navigated spiral fMRI: interleaved versus single-shot. Magn Reson Med. 1998;39(3):361-368. (Pubitemid 28128378)
16. Heaton RK. Wisconsin Card Sorting Test Computer Version 4-Research Edition (WCST:CV4). Odessa, FL: Psychological Assessment Resources, Inc; 2004.
17. Wechsler D. Wechsler Adult Intelligence Scale. 4th ed. San Antonio, TX: The Psychological Corporation; 2008.
18. Homack S, Lee D, Riccio CA. Test review: Delis-Kaplan Executive Function System. J Clin Exp Neuropsychol. 2005;27(5):599-609. (Pubitemid 40896473)
19. Guy S, Isquith P, Gioia G. Behavioral Rating Inventory of Executive Function (BRIEF). Lutz, FL: Psychological Assessment Resources, Inc; 2000.
20. Aghakhani A, Chan EK. Test reviews. In: Bracken BA, Howell K. Clinical Assessment of Depression. Odessa, FL: Psychological Assessment Resources, Inc; 2007:416-422.
21. McGonigle DJ, Howseman AM, Athwal BS, Friston KJ, Frackowiak RSJ, Holmes AP. Variability in fMRI: an examination of intersession differences. Neuroimage. 2000;11(6, pt 1):708-734. (Pubitemid 30437662)
22. Friston KJ, Penny W. Posterior probability maps and SPMs. Neuroimage. 2003;19(3):1240-1249. (Pubitemid 36918260)
23. Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res. 2009;151:387-419.
24. Bigler ED. Neuropsychology and clinical neuroscience of persistent postconcussive syndrome. J Int Neuropsychol Soc. 2008;14(1):1-22.
25. Seigers R, Schagen SB, Coppens CM, et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res. 2009;201(2):279-284.
26. Seigers R, Schagen SB, Beerling W, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res. 2008;186(2):168-175. (Pubitemid 350122748)
27. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006;85(1):66-75. (Pubitemid 44802737)
28. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5(7):22. doi:10.1186/jbiol50.
29. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19(5):1455-1461. (Pubitemid 32202553)
30. Petrides M. Lateral prefrontal cortex: architectonic and functional organization. Philos Trans R Soc Lond B Biol Sci. 2005;360(1456):781-795. (Pubitemid 40885665)
31. Correia SC, Santos RX, Cardoso S, et al. Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease? Curr Aging Sci. 2010;3(2):113-126.
32. Palmer JL, Trotter T, Joy AA, Carlson LE. Cognitive effects of tamoxifen in premenopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2(4):275-282.
33. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294-1300.
34. Hanakawa T, Honda M, Sawamoto N, et al. The role of rostral Brodmann area 6 in mental-operation tasks: an integrative neuroimaging approach. Cereb Cortex. 2002;12(11):1157-1170. (Pubitemid 35191417)
35. Menon V, Adleman NE, White CD, Glover GH, Reiss AL. Error-related brain activation during a Go/NoGo response inhibition task. Hum Brain Mapp. 2001;12(3):131-143. (Pubitemid 32186917)
36. Tsukiura T, Fujii T, Takahashi T, et al. Neuroanatomical discrimination between manipulating and maintaining processes involved in verbal working memory; a functional MRI study. Brain Res Cogn Brain Res. 2001;11(1):13-21. (Pubitemid 32182400)
37. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015-2028.